BLACK LION EDGE

EPIVYN

Anti-Cancer Drugs

Patented Technology

Investors

Licensing Program

EPIVYN Program

Fact Sheet

Media

..............................................

Investing in Black Lion Pharmaceuticals

Black Lion Pharmaceuticals Corporation  is committed to the development of pharmaceuticals devoted to treat cancer and improve quality of life. Our corporate headquarters is based in San Jose, California. We are a novel corporation that shares a vision of leadership through technological innovation and scientific development. At our current growth stage we are only considering investors and venture capitalist that have interest, expertise, organization and the financial resources necessary to partner with Black Lion in order to attain leadership in the pharmaceutical market. Below you will find a brief description of some of our pharmaceutical products.  

New Patented Anti-Cancer Drug EPIVYN

EPIVYN is Black Lion's novel patented anti-cancer drug that is a first generation of high specialized pharmaceuticals that we have called Low Toxicity Anti-Cancer Drugs (LTACD) especially designed to aggressively induce cancer cell death while exhibiting low toxicity to normal cells.

Our novel and proprietary pharmaceutical product EPIVYN has demonstrated anti-cancer effects by inducing a high affinity apoptosis on cancer cells at doses that illicit non-toxic/apoptotic effects against non-cancer cells. EPIVYN has superior anti-cancer results when compared to established chemotherapy drugs including market leaders Methotrexate, Cisplatin and other major drugs.  

Black Lion Pharmaceuticals is a privately held corporation that focuses exclusively in the development of drugs and molecules that are targeted to be future cancer treatment leaders and that will improve the quality of life of millions of patients that unfortunately suffer this disease worldwide.  

Our current expansion phase can be further enhanced with proper and strategic financial backing by investors that seek to ally with Black Lion Pharmaceuticals in generating and distributing pharmaceutical products for the global market. Our investment team can provide you with our corporate information, pharmaceutical products and our global market goals. For more information contact our investment telephone number at  (408) 461-0432 or email us at investors@blacklionpharmaceuticals.com